Clinical trials: Age-Related Maculopathy
Wet Macular Degeneration
A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.
This study will evaluate the efficacy, safety, durability, and pharmacokinetics of KSI-301 administered at 12, 16 and 20 weeks intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in…
- Trial name
- DAZZLE (NCT04049266)
- Testing
- KSI-301, Aflibercept
- Where
- 75 sites in United States, Czechia and 5 more
- Volunteers
- 559 people
- Sponsor
- Kodiak Sciences Inc
Geographic Atrophy
A Study of NGM621 in Participants With Geographic Atrophy
This is a multi-center evaluation of NGM621 in a randomized, double-masked, sham-controlled study in participants with Geographic Atrophy secondary to Age-related Macular Degeneration.
- Trial name
- CATALINA (NCT04465955)
- Testing
- NGM621
- Where
- 65 sites in United States
- Volunteers
- 320 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Wet Age Related Macular Degeneration
Safety and Tolerability of Ranibizumab in Mono/Bilateral Wet Age Related Macular Degeneration (w-AMD) Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye
The purpose of this study is to evaluate the safety and efficacy of ranibizumab in patients affected by wet age related macular degeneration (wAMD).
- Trial name
- TWEYES (NCT01986907)
- Testing
- ranibizumab
- Where
- 101 sites in Italy
- Volunteers
- 1,049 people
- Sponsor
- Novartis Pharmaceuticals
Neovascular Age-related Macular Degeneration
A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
This main long-term extension study is designed to evaluate the long-term safety and tolerability of faricimab 6 milligrams (mg) administered by intravitreal injection at a personalized treatment interval (PTI) to participants…
- Trial name
- AVONELLE-X (NCT04777201)
- Testing
- Faricimab, Anti-VEGF Therapy
- Where
- 251 sites in United States, Argentina and 25 more
- Volunteers
- 1,036 people
- Sponsor
- Hoffmann-La Roche
Macular Degeneration, Choroidal Neovascularization
Safety and Preliminary Efficacy Study of WST11 (Stakel®)-Mediated VTP Therapy in Subjects With CNV Associated With AMD
The objectives of this study are to evaluate the safety(first objective) and efficacy(second objective)of an experimental drug product,Stakel®, in the treatment of neovascular Age related Macular Degeneration (AMD).
- Trial name
- NCT01021956
- Testing
- STAKEL
- Where
- 4 sites in United States, France
- Volunteers
- 10 people
- Sponsor
- Steba Biotech S.A.
Geographic Atrophy
Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
This is a 24-month, Phase III, multicenter, randomized, double-masked, sham-injection controlled study to assess the efficacy and safety of multiple IVT injections of APL-2 in subjects with GA secondary to AMD.
- Trial name
- NCT03525600
- Testing
- APL-2
- Where
- 141 sites in United States, Argentina and 13 more
- Volunteers
- 621 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Age-Related Macular Degeneration
A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration
The objectives of this study are to evaluate the safety and efficacy of E10030 intravitreous injection when administered in combination with Lucentis® against a control of Lucentis® alone in subjects with subfoveal choroidal…
- Trial name
- NCT01089517
- Testing
- E10030 plus Lucentis, Lucentis
- Where
- United States
- Volunteers
- 449 people
- Sponsor
- Ophthotech Corporation